US Patent 8,299,298: Ferric Citrate Claims, Scope, Expiration, and Patent Landscape

US Patent 8,299,298 protects pharmaceutical compositions containing ferric citrate with a BET active surface area of at least 16 m²/g. The patent also claims a narrower intrinsic dissolution-rate range, specified daily doses, 500-mg unit doses, and capsule formulations. Its commercial relevance is tied primarily to Auryxia, ferric citrate, marketed by Keryx Biopharmaceuticals, now part of Akebia Therapeutics.

The core risk is composition-based. A product can potentially fall within claim 1 without using the same trade name, tablet design, or manufacturing process if its ferric citrate satisfies the surface-area limitation and the product is intended to reduce serum phosphate.

What does US Patent 8,299,298 protect?

The patent protects ferric citrate pharmaceutical compositions defined by both chemical identity and physical performance characteristics.

Claim	Main limitation	Scope
1	Ferric citrate with BET active surface area of at least 16 m²/g, a pharmaceutically suitable carrier, and an amount effective to reduce serum phosphate	Broadest independent composition claim
2	Claim 1 composition with intrinsic dissolution rate of 1.88-4.0 mg/cm²/min	Narrows claim 1 by dissolution performance
3	Claim 1 composition administered at 2-30 g/day	Broad dose range
4	Claim 1 composition administered at 4-15 g/day	Intermediate dose range
5	Claim 1 composition administered at 2-12 g/day	Overlapping dose range
6	Claim 1 composition administered at 2, 4, or 6 g/day	Selected dose levels
7	Claim 1 composition administered at 1 g/day	Separate low-dose limitation
8	Claim 1 composition containing 500 mg ferric citrate per unit dosage form	Unit-dose limitation
9	500 mg ferric citrate, BET surface area of at least 16 m²/g, carrier, and capsule dosage form	Narrow capsule composition claim

Claim 1 is the principal commercial claim. Claims 2-9 narrow the protected subject matter but create multiple infringement pathways for products using the claimed ferric citrate material.

The patent does not claim ferric citrate generically. It claims ferric citrate having a specified BET active surface area. That physical-property limitation distinguishes the claimed material from ferric citrate preparations with lower surface area or materially different particle characteristics.

How does the BET surface-area limitation affect infringement?

The BET limitation requires the accused ferric citrate to have an active surface area of at least 16 m²/g. BET surface area is generally measured through gas adsorption, commonly nitrogen adsorption, using the Brunauer-Emmett-Teller method.

The limitation creates several technical and legal issues:

The relevant measurement is the surface area of the ferric citrate, not necessarily the total surface area of the finished tablet or capsule.
Particle size, porosity, aggregation, hydration state, milling, drying, and storage can affect the measured value.
Testing conditions and sample preparation can materially influence the result.
A product may infringe even if its label does not disclose the BET value, provided testing establishes that the material meets the limitation.
A batch-to-batch range matters. Consistent measurements below 16 m²/g may support a non-infringement position; intermittent or borderline results create litigation risk.

A generic applicant would typically evaluate the API and finished dosage form separately. If the ferric citrate input meets the 16 m²/g threshold, the carrier and therapeutic-use limitations may complete the claim.

What does the intrinsic dissolution-rate claim cover?

Claim 2 requires an intrinsic dissolution rate of 1.88-4.0 mg/cm²/min in addition to the claim 1 limitations.

Intrinsic dissolution rate measures dissolution from a constant surface area under specified conditions. The range is narrower than claim 1’s BET requirement and can operate as an additional technical signature of the ferric citrate material.

The principal litigation questions would include:

Whether the patent specifies an adequately reproducible test method.
Whether pH, buffer, agitation, temperature, compression force, and exposed surface area are controlled.
Whether the accused product’s result falls within the range.
Whether the range is measured on ferric citrate itself or a formulated product.
Whether a value outside the range avoids claim 2 while remaining within claim 1.

A product can therefore avoid claim 2 and still face claim 1 exposure if its BET active surface area is at least 16 m²/g.

How do the dosing claims overlap?

Claims 3-7 create overlapping and non-overlapping dose limitations.

Dose	Claim coverage
500 mg per unit	Claim 8, if the other claim 1 conditions are met
1 g/day	Claim 7
2 g/day	Claims 3, 5, and 6
4 g/day	Claims 3, 4, 5, and 6
6 g/day	Claims 3, 4, 5, and 6
12 g/day	Claims 3, 4, and 5
15 g/day	Claims 3 and 4
30 g/day	Claim 3

Claims 3-5 are overlapping dependent claims. That redundancy can provide multiple claim positions around common clinical dosing. Claim 6 is more specific and covers selected doses expressly recited in the claim. Claim 7 is distinct because 1 g/day falls below the 2-g/day floor in claims 3-6.

The daily-dose claims are composition claims dependent on claim 1. They do not independently protect every use of ferric citrate at the stated dose. The accused product must still contain ferric citrate meeting the BET requirement, include a pharmaceutically suitable carrier, and be present in an amount effective to reduce serum phosphate.

What formulations are protected by US 8,299,298?

The patent covers compositions containing a pharmaceutically suitable carrier. The claims supplied do not require a particular excipient, release profile, coating, tablet hardness, capsule shell, or manufacturing process.

Potentially relevant dosage forms include:

Capsules under claim 9.
Tablets, if they satisfy claim 1 and any applicable dose limitations.
Granules, powders, sachets, or other oral solid dosage forms.
Formulations using conventional pharmaceutical excipients.
500-mg unit doses under claim 8, regardless of whether the final product is a capsule or tablet, subject to the remaining claim elements.

Claim 9 is narrower than claim 8 because it requires a capsule dosage form. A tablet product may avoid claim 9 but still implicate claims 1 or 8.

The claims supplied do not expressly require a specific ferric-to-citrate ratio, elemental iron content, excipient, tablet weight, coating, or dissolution profile except for claim 2’s intrinsic dissolution-rate range.

What is the relationship to Auryxia and ferric citrate?

Auryxia is ferric citrate, marketed in 210-mg ferric-citrate tablets in the United States. The product is approved for control of serum phosphorus levels in adults with chronic kidney disease on dialysis and for treatment of iron-deficiency anemia in adults with chronic kidney disease not on dialysis. The approved label identifies the active ingredient as ferric citrate and describes the product as an oral tablet formulation [1].

The supplied claims are directed to the phosphate-lowering composition concept. The claims do not, on their face, require the iron-deficiency-anemia indication. A product marketed only for iron-deficiency anemia could still face composition-claim exposure if it satisfies the claimed material and formulation limitations, although the “amount effective to reduce serum phosphate levels” limitation would require factual and claim-construction analysis.

When does US Patent 8,299,298 lose exclusivity?

The patent issued on October 30, 2012. Public patent records identify a September 7, 2005 priority date for the relevant ferric citrate invention and a U.S. patent-term framework generally tied to the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, patent-term extension, and other statutory adjustments [2][3].

The commercial patent term should be checked against the current FDA Orange Book listing and USPTO patent records. Patent expiry is not identical to FDA drug exclusivity. FDA approval exclusivity may expire earlier than the patent term, and a patent may remain enforceable after an NDA’s regulatory exclusivity period ends.

For investment and launch analysis, the relevant distinction is:

Exclusivity type	Relevance
Patent term	Determines enforceable patent rights, subject to litigation outcomes and statutory adjustments
FDA new-drug exclusivity	Controls certain abbreviated applications and regulatory timing
Pediatric exclusivity	Can add six months if granted
Orphan exclusivity	Applies only if the statutory orphan designation and indication requirements are satisfied
Orange Book listing	Gives the patent notice and Paragraph IV litigation significance for ANDA applicants

What is the Orange Book status of US 8,299,298?

Auryxia’s FDA regulatory record and Orange Book listing are central to generic-entry analysis. An Orange Book-listed patent can trigger the ANDA Paragraph IV framework if a generic applicant certifies that the patent is invalid, unenforceable, or will not be infringed.

The listing must be evaluated together with:

The patent number and expiration date shown in the current Orange Book.
The associated use code, if the patent is listed for a method of use.
Whether the patent is listed against the relevant NDA strength or dosage form.
Any FDA-recognized patent-term extension or pediatric extension.
The applicant’s Paragraph IV notice and the NDA holder’s response.

The claims supplied are composition claims, not purely method-of-use claims. That distinction matters because composition claims can create broader exposure across indications than a use-code-limited patent.

Which companies have challenged Auryxia patents?

Auryxia has faced generic competition and patent challenges associated with abbreviated new drug applications. Publicly reported litigation involving Auryxia has included challenges by generic-drug companies such as Teva, Lupin, Zydus, and related applicants. The exact patent claims, settlement terms, launch dates, and court outcomes differ by defendant and should be assessed from the individual district-court docket and settlement record.

A Paragraph IV filing does not itself invalidate the patent or establish non-infringement. It creates a statutory notice event and can trigger a 30-month stay of FDA approval if the NDA holder files a timely infringement action under the Hatch-Waxman framework [4].

What patent litigation affects US 8,299,298?

The relevant litigation questions are:

Whether the generic ferric citrate has a BET surface area of at least 16 m²/g.
Whether the generic applicant’s product contains the claimed ferric citrate material or a materially different material.
Whether “effective to reduce serum phosphate levels” is satisfied by the proposed label and intended use.
Whether the claims are enabled across the full BET and dose ranges.
Whether the specification adequately describes the claimed physical properties.
Whether prior art disclosed ferric citrate compositions with the claimed surface area or dissolution behavior.
Whether the patent’s claims are anticipated or obvious over earlier ferric citrate formulations and phosphate-binder disclosures.
Whether testing supports infringement under the selected analytical methods.

For an ANDA applicant, an Abbreviated New Drug Application patent certification is usually based on the proposed product and labeling. The applicant’s Paragraph IV position may assert that the patent is invalid, unenforceable, or not infringed. The NDA holder may rely on batch testing, discovery concerning API manufacture, and the proposed label.

How strong is the patent estate for ferric citrate?

US 8,299,298 has meaningful claim breadth because claim 1 combines a measurable material property with a conventional pharmaceutical composition. Its strengths include:

Coverage of the active ingredient’s physical characteristics.
No requirement for a particular brand, indication, or excipient.
Dependent claims covering standard dose levels.
Specific protection for 500-mg unit doses.
Capsule coverage through claim 9.

Its vulnerabilities include:

Dependence on reproducible BET testing.
Potential disputes over analytical methodology.
Possible prior-art challenges involving high-surface-area ferric citrate.
The functional phrase requiring an amount effective to reduce serum phosphate.
The possibility of designing around the 16 m²/g threshold.
The age of the patent and the approaching or reached end of its ordinary patent term.

The patent is stronger against a product that uses the same high-surface-area ferric citrate material and a 500-mg oral unit dose. It is weaker against a product that uses a demonstrably lower-surface-area material, avoids the claimed dissolution range, and relies on a label that does not support phosphate reduction, subject to the evidence and claim construction.

What generic launch risks exist?

Generic launch risk depends on four variables:

Risk factor	Business effect
API BET surface area at or above 16 m²/g	Increases literal infringement risk under claim 1
500-mg unit dose	Increases exposure under claim 8
Capsule dosage form	Creates additional claim 9 exposure
Phosphate-binder labeling	Supports the functional limitation and increases use-related risk

A non-infringing design may attempt to use ferric citrate below the claimed BET threshold. That strategy carries formulation and bioavailability risks because surface area can affect dissolution and therapeutic performance. A different particle-engineering process may also create separate process, formulation, or regulatory comparability issues.

How does this patent compare with method-of-use and formulation patents?

US 8,299,298 is principally a composition patent tied to physical characteristics of ferric citrate. Method-of-use patents generally protect administering ferric citrate for a specified disease, patient population, or therapeutic endpoint. Formulation patents generally protect excipient combinations, release profiles, coating systems, dosage forms, or manufacturing processes.

Patent category	Typical protected subject matter	Generic design-around potential
US 8,299,298-type composition claim	Ferric citrate with specified BET surface area and carrier	Change material properties or challenge testing
Method-of-use patent	Phosphate control, CKD, dialysis, or anemia treatment	Use a different label or pursue a different indication
Formulation patent	Tablet, capsule, excipient, coating, or release profile	Modify formulation architecture
Process patent	Milling, drying, crystallization, or particle preparation	Use an alternative manufacturing route

A complete freedom-to-operate analysis must review the entire Auryxia patent family, continuations, divisionals, related U.S. patents, foreign counterparts, and any later-filed formulation or manufacturing patents. US 8,299,298 should not be treated as the entire ferric citrate estate.

Key Takeaways

US 8,299,298 centers on ferric citrate with a BET active surface area of at least 16 m²/g.
Claim 1 is the broadest and most commercially important claim.
Claim 2 adds an intrinsic dissolution-rate range of 1.88-4.0 mg/cm²/min.
Claims 3-7 cover daily doses from 1 g/day through 30 g/day, with substantial overlap.
Claim 8 covers a 500-mg ferric citrate unit dosage form.
Claim 9 specifically covers a 500-mg capsule containing the claimed high-surface-area ferric citrate.
The principal technical dispute is likely to involve BET measurement, batch variability, and API characterization.
The patent is relevant to Auryxia and generic ferric citrate products using the phosphate-lowering label.
Orange Book status, patent-term adjustments, Paragraph IV certifications, and settlement agreements must be reviewed together.
A product using ferric citrate below 16 m²/g may have a potential design-around, but it can face performance and regulatory comparability issues.

FAQs About US Patent 8,299,298

Does US 8,299,298 cover all ferric citrate products?

No. The claims require ferric citrate with a BET active surface area of at least 16 m²/g, along with the stated carrier and therapeutic limitations.

Does a ferric citrate tablet infringe claim 9?

Not necessarily. Claim 9 requires a capsule dosage form. A tablet could still implicate claim 1 or claim 8 if it satisfies those limitations.

Can a generic avoid the patent by using a different excipient?

Not necessarily. Claim 1 requires a pharmaceutically suitable carrier but does not appear limited to a particular excipient. Changing the carrier may not avoid infringement if the ferric citrate and other claim elements remain unchanged.

Is the 500-mg limitation the same as the Auryxia tablet strength?

No. Auryxia labeling identifies ferric citrate strength by ferric citrate content and elemental iron content. The patent claim must be compared with the product’s actual claimed quantity and not with a tablet-strength description alone [1].

Does a Paragraph IV challenge immediately permit generic launch?

No. A Paragraph IV certification can trigger litigation and an FDA approval stay. Launch timing depends on litigation, settlement terms, regulatory approval, patent expiry, and any applicable exclusivity period [4].

References

U.S. Food and Drug Administration. (2023). Auryxia (ferric citrate) tablets: Prescribing information.
United States Patent and Trademark Office. (2012). U.S. Patent No. 8,299,298, Ferric citrate compositions and methods of use thereof.
United States Code. (2023). 35 U.S.C. §§ 154, 156, and 163: Patent term and patent-term extension.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004213819	⤷ Start Trial
Australia	2006279333	⤷ Start Trial
Australia	2007210090	⤷ Start Trial
Australia	2007210096	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,299,298

Summary for Patent: 8,299,298